SentenceSentimentTitleUrlDate
CHICAGO Gilead Sciences Inc said on Monday that a latestage study of a key experimental drug aimed at treating NASH a progressive fatty liver disease failed to meet its main goal sending the companys shares down 4 NegativeCHICAGO Gilead Sciences Inc said on Monday that a latestage study of a key experimental drug aimed at treating NASH a progressive fatty liver disease failed to meet its main goal sending the companys shares down 4 http://www.reuters.com/news/health/article/us-gileadsciences-nash/gilead-misses-key-goal-in-nash-liver-disease-trial-shares-sink-idUSKCN1Q02HU2019-02-12
Analysts have projected the market for NASH treatments to reach billion to billion as populations with fatty diets increasingly develop the disease NeutralCHICAGO Gilead Sciences Inc said on Monday that a latestage study of a key experimental drug aimed at treating NASH a progressive fatty liver disease failed to meet its main goal sending the companys shares down 4 http://www.reuters.com/news/health/article/us-gileadsciences-nash/gilead-misses-key-goal-in-nash-liver-disease-trial-shares-sink-idUSKCN1Q02HU2019-02-12